Almanack Investment Partners LLC. Has $445,000 Position in Novartis AG $NVS

Almanack Investment Partners LLC. increased its position in shares of Novartis AG (NYSE:NVS) by 25.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,678 shares of the company’s stock after purchasing an additional 735 shares during the period. Almanack Investment Partners LLC.’s holdings in Novartis were worth $445,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC increased its stake in Novartis by 76.5% during the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock worth $599,000 after acquiring an additional 2,666 shares during the period. Wealthcare Advisory Partners LLC increased its stake in Novartis by 9.0% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 3,041 shares of the company’s stock worth $339,000 after acquiring an additional 252 shares during the period. GAMMA Investing LLC increased its stake in Novartis by 29.9% during the 1st quarter. GAMMA Investing LLC now owns 6,524 shares of the company’s stock worth $727,000 after acquiring an additional 1,500 shares during the period. CRA Financial Services LLC bought a new position in Novartis during the 1st quarter worth $209,000. Finally, D Orazio & Associates Inc. increased its stake in Novartis by 2.9% during the 1st quarter. D Orazio & Associates Inc. now owns 3,795 shares of the company’s stock worth $423,000 after acquiring an additional 108 shares during the period. 13.12% of the stock is owned by institutional investors and hedge funds.

Novartis Trading Down 0.8%

Shares of NVS opened at $130.05 on Monday. Novartis AG has a 52-week low of $96.06 and a 52-week high of $133.55. The business’s fifty day moving average is $125.14 and its 200-day moving average is $117.96. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.62 and a current ratio of 0.82. The firm has a market cap of $274.72 billion, a price-to-earnings ratio of 18.93, a PEG ratio of 1.80 and a beta of 0.64.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Thursday, July 17th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Novartis had a return on equity of 41.08% and a net margin of 25.64%.The business had revenue of $14.05 billion for the quarter, compared to analyst estimates of $13.94 billion. During the same quarter in the previous year, the company posted $1.97 EPS. Novartis’s quarterly revenue was up 12.3% compared to the same quarter last year. Equities analysts anticipate that Novartis AG will post 8.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on NVS shares. Weiss Ratings restated a “buy (b)” rating on shares of Novartis in a research note on Wednesday, October 8th. Wall Street Zen upgraded Novartis from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Novartis in a research note on Thursday, August 21st. Morgan Stanley upgraded Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 price target on the stock in a research note on Friday, August 8th. Finally, The Goldman Sachs Group reiterated a “sell” rating and issued a $118.00 price target (down previously from $119.00) on shares of Novartis in a research note on Friday, September 12th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $120.33.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.